Ameriprise
GNCA

Ameriprise’s Genocea Biosciences, Inc. GNCA Stock Holding History

Ameriprise’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,654
Closed -$32K – 3782
2017
Q3 		$32K Sell
2,654
-125
-4% -$4.74K ﹤0.01% 3647
2017
Q2 		$119K Buy
2,779
+287
+12% +$13.8K ﹤0.01% 3641
2017
Q1 		$121K Buy
2,492
+634
+34% +$24.8K ﹤0.01% 3539
2016
Q4 		$61K Sell
1,858
-1,080
-37% -$35.6K ﹤0.01% 3794
2016
Q3 		$172K Sell
2,938
-2,312
-44% -$90.7K ﹤0.01% 3588
2016
Q2 		$156K Buy
+5,250
New +$192K ﹤0.01% 3582

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Ameriprise's GNCA Position: Q4 2017 in Review

Ameriprise sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2017, closing a stake of 2,654 shares — an estimated $32K sold.

Ameriprise first reported a position in GNCA in Q2 2016 and held it in 6 quarters. The position peaked at $172K in Q3 2016. 56 funds tracked by Wall St. Rank hold GNCA as of Q4 2017.

  • Ameriprise reported no remaining Genocea Biosciences, Inc. position as of Q4 2017 after selling out during the quarter.
  • Ameriprise sold 2,654 Genocea Biosciences, Inc. shares in Q4 2017, an estimated $32K.
  • Ameriprise first reported a position in Genocea Biosciences, Inc. in Q2 2016 and held it in 6 quarters.
  • Ameriprise's Genocea Biosciences, Inc. position peaked at $172K in Q3 2016.
  • 56 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2017.

Based on Ameriprise's 13F filing for Q4 2017, filed 12 Feb 2018.